AXL

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

Retrieved on: 
Monday, November 6, 2023
MSD, OSE, Asian literature, ESMO, Pembrolizumab, Data, KEAP1, Merck, Non-small-cell lung cancer, Immunotherapy, STK11, Merck Sharp & Dohme Federal Credit Union, Patient, AXL, Merck & Co., Pharmaceutical industry, NSCLC

BERGEN, Norway, Nov. 6, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)  in second line Non-Small Cell Lung Cancer (NSCLC) patients was presented on November 4th at the 2023 Society of Immunotherapy of Cancer Annual Meeting.

Key Points: 
  • The pre-planned biomarker analysis of the BGBC008 study in 2L NSCLC patients adds to the clinical data recently announced at the 2023 ESMO meeting.
  • The poster presentation entitled "Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC patients harboring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 Trial", is now available on BerGenBio's website under the Scientific Publications section.
  • Martin Olin, Chief Executive Officer of BerGenBio, commented "The findings add to the industry's understanding of the outcomes in 2L NSCLC patients and the potential for bemcentinib to benefit patients in combination with immune checkpoint inhibition.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

Retrieved on: 
Monday, November 6, 2023
MSD, OSE, Asian literature, ESMO, Pembrolizumab, Data, KEAP1, Merck, Non-small-cell lung cancer, Immunotherapy, STK11, Merck Sharp & Dohme Federal Credit Union, Patient, AXL, Merck & Co., Pharmaceutical industry, NSCLC

BERGEN, Norway, Nov. 6, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)  in second line Non-Small Cell Lung Cancer (NSCLC) patients was presented on November 4th at the 2023 Society of Immunotherapy of Cancer Annual Meeting.

Key Points: 
  • The pre-planned biomarker analysis of the BGBC008 study in 2L NSCLC patients adds to the clinical data recently announced at the 2023 ESMO meeting.
  • The poster presentation entitled "Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC patients harboring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 Trial", is now available on BerGenBio's website under the Scientific Publications section.
  • Martin Olin, Chief Executive Officer of BerGenBio, commented "The findings add to the industry's understanding of the outcomes in 2L NSCLC patients and the potential for bemcentinib to benefit patients in combination with immune checkpoint inhibition.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

Retrieved on: 
Tuesday, October 31, 2023
MSD, OSE, NSCLC, Pembrolizumab, Merck, Journal, SITC, Non-small-cell lung cancer, Immunotherapy, JITC, ASA, Merck Sharp & Dohme Federal Credit Union, Society, Society for Immunotherapy of Cancer, Patient, AXL, Merck & Co., Pharmaceutical industry, Cancer

BERGEN, Norway, Oct. 31, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL inhibitor in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.

Key Points: 
  • BERGEN, Norway, Oct. 31, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL inhibitor in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.
  • The poster abstract was published today in the Journal for Immunotherapy of Cancer (JITC), an open-access journal.
  • The full poster will be available on BerGenBio's website shortly following presentation on November 4th.
  • Title:  Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC patients harboring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial
    KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

Retrieved on: 
Tuesday, October 31, 2023
MSD, OSE, NSCLC, Pembrolizumab, Merck, Journal, SITC, Non-small-cell lung cancer, Immunotherapy, JITC, ASA, Merck Sharp & Dohme Federal Credit Union, Society, Society for Immunotherapy of Cancer, Patient, AXL, Merck & Co., Pharmaceutical industry, Cancer

BERGEN, Norway, Oct. 31, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL inhibitor in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.

Key Points: 
  • BERGEN, Norway, Oct. 31, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL inhibitor in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.
  • The poster abstract was published today in the Journal for Immunotherapy of Cancer (JITC), an open-access journal.
  • The full poster will be available on BerGenBio's website shortly following presentation on November 4th.
  • Title:  Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC patients harboring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial
    KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Retrieved on: 
Monday, October 23, 2023
OSE, Data analysis, ESMO, Publication, Pembrolizumab, Assistant professor, Non-small-cell lung cancer, STK11, Haukeland University Hospital, Melanoma, European Society for Medical Oncology, Patient, AXL, Pharmaceutical industry, Medical device, NSCLC

In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.

Key Points: 
  • In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.
  • These data provide a strong foundation for further clinical investigations of bemcentinib in NSCLC patients with high unmet needs, including those with STK11 mutations."
  • Dr. Oliva continued, "During the meeting, our collaborator, Dr. Oddbjorn Straume, also presented data on the combination of bemcentinib with standard of care therapies in first line and second line melanoma patients.
  • In totality, these new data substantiate BerGenBio's focused strategy on the treatment of first line NSCLC patients with STK11m patients in our on-going BGBC016 study."

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Retrieved on: 
Monday, October 23, 2023
OSE, Data analysis, ESMO, Publication, Pembrolizumab, Assistant professor, Non-small-cell lung cancer, STK11, Haukeland University Hospital, Melanoma, European Society for Medical Oncology, Patient, AXL, Pharmaceutical industry, Medical device, NSCLC

In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.

Key Points: 
  • In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.
  • These data provide a strong foundation for further clinical investigations of bemcentinib in NSCLC patients with high unmet needs, including those with STK11 mutations."
  • Dr. Oliva continued, "During the meeting, our collaborator, Dr. Oddbjorn Straume, also presented data on the combination of bemcentinib with standard of care therapies in first line and second line melanoma patients.
  • In totality, these new data substantiate BerGenBio's focused strategy on the treatment of first line NSCLC patients with STK11m patients in our on-going BGBC016 study."

AAM to Announce Third Quarter Financial Results on November 3

Retrieved on: 
Friday, October 20, 2023
AAM, American Axle, NYSE, AXL

DETROIT, Oct. 20, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss third quarter results and other related matters at 10:00 a.m.

Key Points: 
  • DETROIT, Oct. 20, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss third quarter results and other related matters at 10:00 a.m.
  • A press release announcing the results will be issued before the market opens on the same day and will be available at www.aam.com .
  • To participate by live audio webcast or listen to the briefing following the call, visit investor.aam.com.
  • To listen to the replay please dial:
    When prompted, callers should enter replay access code 5629227.

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Retrieved on: 
Monday, October 16, 2023
AXL, Vall d'Hebron University Hospital, NSCLC, Trial of the century, Haukeland University Hospital, Lung cancer, Teaching hospital, OSE, ESMO, Vall, Assistant professor, Nursing, Patient, Poster, Pharmaceutical industry

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Key Points: 
  • BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
  • Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron University Hospital, Spain will present the following poster summarizing the final results from the BGBC008 Phase II study of bemcentinib in combination with pembrolizumab in 2L NSCLC:
    Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
    The poster will be available on BerGenBio's website shortly following presentation.
  • In addition, Dr.  Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway will make an oral presentation summarizing the results of the Investigator Led Study LBA52 with bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L metastatic melanoma patients:
    Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to share more data on bemcentinib which we believe substantiates our strategy to focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of potentiating the effects of standard of care treatments.
  • We thank the patients who participated in these studies, their families, and all participating investigators as well as their clinical and nursing staff for contributing to our understanding of bemcentinib as a potential cancer therapeutic."

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Retrieved on: 
Monday, October 16, 2023
AXL, Vall d'Hebron University Hospital, NSCLC, Trial of the century, Haukeland University Hospital, Lung cancer, Teaching hospital, OSE, ESMO, Vall, Assistant professor, Nursing, Patient, Poster, Pharmaceutical industry

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Key Points: 
  • BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
  • Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron University Hospital, Spain will present the following poster summarizing the final results from the BGBC008 Phase II study of bemcentinib in combination with pembrolizumab in 2L NSCLC:
    Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
    The poster will be available on BerGenBio's website shortly following presentation.
  • In addition, Dr.  Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway will make an oral presentation summarizing the results of the Investigator Led Study LBA52 with bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L metastatic melanoma patients:
    Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to share more data on bemcentinib which we believe substantiates our strategy to focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of potentiating the effects of standard of care treatments.
  • We thank the patients who participated in these studies, their families, and all participating investigators as well as their clinical and nursing staff for contributing to our understanding of bemcentinib as a potential cancer therapeutic."

Music China 2023 New Regression

Retrieved on: 
Wednesday, September 27, 2023
KHS, Pioneer DJ, Ocean, Yamaha, Samick, AXL, Fender, Rock the Ocean's Tortuga Music Festival, VIP, Ikutaro Kakehashi, Nightclub, Medeli

SHANGHAI, Sept. 27, 2023 /PRNewswire/ -- Music China will return on October 11th -14th, 2023, at the Shanghai New International Exhibition Centre (SNIEC).

Key Points: 
  • SHANGHAI, Sept. 27, 2023 /PRNewswire/ -- Music China will return on October 11th -14th, 2023, at the Shanghai New International Exhibition Centre (SNIEC).
  • Music China will build up the bridge for you to meet over 1,500 top-tier musical instruments suppliers from over 22 countries and regions through networking sessions and scheduled one-to-one meetings.
  • Music China 2023 provides a total exhibition area of 120,000 square meters, with 10 indoor pavilions and outdoor exhibition areas.
  • Attendee registration and hosted buyer application for Music China 2023 is open now.